Urea standard Kt/Vurea for assessing dialysis treatment adequacy

Hemodialysis International

Volumn 8, Issue 2, 2004, Pages 193-197

  Leypoldt, John Ken ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Clearance; Dose; Protein bound; Toxins; Water soluble

Indexed keywords

HIPPURIC ACID; INDICAN; INDOLEACETIC ACID; NITROGEN; PARA CRESOL; UREA; UREMIC TOXIN;

ALGORITHM; COMPARATIVE STUDY; CREATININE CLEARANCE; FREQUENCY ANALYSIS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY CLEARANCE; MATHEMATICAL COMPUTING; NITROGEN CONCENTRATION; PERITONEAL DIALYSIS; REVIEW; TIME; TREATMENT OUTCOME; UREA BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; UREMIA; VALIDATION PROCESS;

EID: 22644442392     PISSN: 14927535     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1492-7535.2004.01095.x     Document Type: Review

References (38)

1. Babb AL, Popovich RP, Christopher TG, Scribner BH. The genesis of the square meter-hour hypothesis. Trans Am Soc Artif Int Organs. 1971; 17: 81-91.
2. Babb AL, Farrell PC, Uvelli DA, Scribner BH. Hemodialyzer evaluation by examination of solute molecular spectra. Trans Am Soc Artif Int Organs. 1972; 18: 98-105.
3. Babb AL, Strand MJ, Uvelli DA, Milutinovic J, Scribner BH. Quantitative description of dialysis treatment: A dialysis index. Kidney Int Suppl. 1975; (2): 23-29.
4. Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int. 1985; 28(3): 526-534.
5. Keshaviah PR, Nolph KD, Van Stone JC. The peak concentration hypothesis: A urea kinetic approach to comparing the adequacy of continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis. Perit Dial Int. 1989; 9(4): 257-260.
6. Gotch FA. The current place of urea kinetic modelling with respect to different dialysis modalities. Nephrol Dial Transplant. 1998; 13(Suppl 6): 10-14.
7. Gotch FA. Modeling the dose of home dialysis. Home Hemodial Int. 1999; 3: 37-40.
8. K/DOQI Clinical Practice Guidelines for Hemodialysis Adequacy: Update 2000. Am J Kidney Dis. 2001; 37(1 Suppl 1): S7-S64.
9. Depner T, Beck G, Daugirdas J, Kusek J, Eknoyan G. Lessons from the Hemodialysis (HEMO) Study: An improved measure of the actual hemodialysis dose. Am J Kidney Dis. 1999; 33(1): 142-149.
10. Sargent JA, Gotch FA. The analysis of concentration dependence of uremic lesions in clinical studies. Kidney Int Suppl. 1975; (2): 35-44.
11. Leypoldt JK, Jaber BL, Zimmerman DL. Predicting treatment dose for novel therapies using urea standard Kt/V. Semin Dial. 2004; in press.
12. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R. Effect of dialysis dose and membrane flux in maintenance hemodialysis. Hemodialysis (HEMO) Study Group. N Engl J Med. 2002; 347(25): 2010-2019.
13. Smye SW, Evans JH, Will E, Brocklebank JT. Paediatric haemodialysis: Estimation of treatment efficiency in the presence of urea rebound. Clin Phys Physiol Meas. 1992; 13(1): 51-62.
14. Daugirdas JT, Schneditz D. Overestimation of hemodialysis dose depends on dialysis efficiency by regional blood flow but not by conventional two pool urea kinetic analysis. ASAIO J. 1995; 41(3): M719-M724.
15. Tattersall JE, DeTakats D, Chamney P, Greenwood RN, Farrington K. The post-hemodialysis rebound: Predicting and quantifying its effect on Kt/V. Kidney Int. 1996; 50(6): 2094-2102.
16. Maduell F, Garcia-Valdecasas I Garcia H, Hernandez-Jaras J, Siguenza F, del Pozo C, Giner R, Moll R, Garrigos E. Validation of different methods to calculate Kt/V considering postdialysis rebound. Nephrol Dial Transplant. 1997; 12(9): 1928-1933.
17. abstract. J Am Soc Nephrol. 13: 413A.
18. abstract. Hemodial Int. 2003; 7(1): 80.
19. Xue JL, Chen SC, Ebben JP, Constantini EG, Everson SE, Frazier ET, Agodoa LY, Collins AJ. Peritoneal and hemodialysis. I. Differences in patient characteristics at initiation. Kidney Int. 2002; 61(2): 734-740.
20. Stack AG. Determinants of modality selection among incident US dialysis patients: Results from a national study. J Am Soc Nephrol. 2002; 13(5): 1279-1287.
21. Bloembergen WE, Port FK, Mauger EA, Wolfe RA. A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol. 1995; 6(2): 177-183.
22. Fenton SS, Schaubei DE, Desmeules M, Morrison HI, Mao Y, Copleston P, Jeffery JR, Kjellstrand CM. Hemodialysis versus peritoneal dialysis: A comparison of adjusted mortality rates. Am J Kidney Dis. 1997; 30(3): 334-342.
23. Vonesh EF, Moran J. Mortality in end-stage renal disease: A reassessment of differences between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol. 1999; 10(2): 354-365.
24. Collins AJ, Hao W, Xia H, Ebben JP, Everson SE, Constantini EG, Ma JZ. Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis. 1999; 34(6): 1065-1074.
25. Tanna MM, Vonesh EF, Korbet SM. Patient survival among incident peritoneal dialysis and hemodialysis patients in an urban setting. Am J Kidney Dis. 2000; 36(6): 1175-1182.
26. Keshaviah P, Collins AJ, Ma JZ, Churchill DN, Thorpe KE. Survival comparison between hemodialysis and peritoneal dialysis based on matched dose of delivered therapy. J Am Soc Nephrol. 2002; 13(Suppl 1): S48-S52.
27. Xue JL, Everson SE, Constantini EG, Ebben JP, Chen SC, Agodoa LY, Collins AJ. Peritoneal and hemodialysis. II. Mortality risk associated with initial patient characteristics. Kidney Int. 2002; 61(2): 741-746.
28. Ganesh SK, Hulbert-Shearon T, Port FK, Eagle K, Stack AG. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J Am Soc Nephrol. 2003; 14(2): 415-424.
29. Termorshuizen F, Korevaar JC, Dekker FW, Van Manen JG, Boeschoten EW, Krediet RT. Hemodialysis and peritoneal dialysis: Comparison of adjusted mortality rates according to the duration of dialysis: Analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis 2. The Netherlands Cooperative Study on the Adequacy of Dialysis Study Group. J Am Soc Nephrol. 2003; 14(11): 2851-2860.
30. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab S, Teehan B, Eknoyan G. Effects of high-flux hemodialysis on clinical outomes: Results of the HEMO Study. J Am Soc Nephrol. 2003; 14(12): 3251-3263.
31. Korevaar JC, Feith GW, Dekker FW, van Manen JG, Boeschoten EW, Bossuyt PM, Krediet RT. Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: A randomized controlled trial. NECOSAD Study Group. Kidney Int. 2003; 64(6): 2222-2228.
32. Dedrick RL. Pharmacokinetic and pharmacodynamic considerations for chronic hemodialysis. Kidney Int Suppl. 1975; (2): 7-15.
33. Shargel L, Yu ABC. Applied Biopharmaceutics and Pharmacokinetics. Norwalk (CT): Appleton & Lange, 1993.
34. Depner TA. Benefits of more frequent dialysis: Lower TAC at the same Kt/V. Nephrol Dial Transplant. 1998; 13(Suppl 6): 20-24.
35. Depner TA. Daily hemodialysis efficiency: An analysis of solute kinetics. Adv Renal Replace Ther. 2001; 8(4): 227-235.
36. Fagugli RM, De Smet R, Buoncristiani U, Lameire N, Vanholder R. Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis. 2002; 40(2): 339-347.
37. Clark WR, Leypoldt JK, Henderson LW, Mueller BA, Scott MK, Vonesh EF. Quantifying the effect of changes in the hemodilaysis prescription on effective solute removal with a mathematical model. J Am Soc Nephrol. 1999; 10(3): 601-609.
38. Goldfarb-Rumyantzev AS, Cheung AK, Leypoldt JK. Computer simulation of small-solute and middle-molecule removal during short daily and long thrice-weekly hemodialysis. Am J Kidney Dis. 2002; 40(6): 1211-1218.